We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LAG3 a novel receptor for misfolded a-synuclein
Product News

LAG3 a novel receptor for misfolded a-synuclein

LAG3 a novel receptor for misfolded a-synuclein
Product News

LAG3 a novel receptor for misfolded a-synuclein


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "LAG3 a novel receptor for misfolded a-synuclein"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A recent study has identified the lymphocyte-activation gene 3 (LAG3) also known as CD223 as the binding receptor for misfolded α-synuclein (Mao et al., Neurodegeneration 2016).


LAG3 is a transmembrane protein belonging to the immunoglobulin superfamily with diverse biologic effects on T cell function.


LAG3 is enriched in the spleen and thymus, and is also expressed in neurons throughout the central nervous system (CNS) including dopaminergic neurons (DAs) which are highly susceptible to degeneration in Parkinson’s disease (PD).


LAG3 was found to associate with and lead to internalization of pathologic, pre-formed fibrils (PFFs) of α-synuclein.


This interaction was proposed as a mechanism for the cell-to-cell transmission of toxic α-synuclein species in neurons, which has been viewed as a potential driver of PD pathogenesis.


These findings highlight a novel CNS function for LAG3, a protein traditionally known to play a role in the immune system.


BioLegend
Learn more about BioLegend’s highly specific antibodies for α-synuclein and LAG3 proteins


BioLegend


Advertisement